Miragen Therapeutics, Inc. (NASDAQ:MGEN) Director Bruce Booth purchased 545,454 shares of the stock in a transaction dated Tuesday, February 13th. The stock was purchased at an average price of $5.50 per share, with a total value of $2,999,997.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Miragen Therapeutics, Inc. (MGEN) remained flat at $$5.50 during trading hours on Tuesday. 236,096 shares of the company were exchanged, compared to its average volume of 312,177. Miragen Therapeutics, Inc. has a 52 week low of $5.01 and a 52 week high of $18.00. The firm has a market cap of $120.03, a price-to-earnings ratio of -0.63 and a beta of 1.44. The company has a current ratio of 7.11, a quick ratio of 7.11 and a debt-to-equity ratio of 0.04.
Large investors have recently added to or reduced their stakes in the stock. Seaward Management Limited Partnership acquired a new position in Miragen Therapeutics during the 3rd quarter valued at approximately $117,000. Russell Investments Group Ltd. acquired a new position in Miragen Therapeutics during the 3rd quarter valued at approximately $147,000. Wells Fargo & Company MN boosted its position in Miragen Therapeutics by 203.8% during the 4th quarter. Wells Fargo & Company MN now owns 17,804 shares of the medical research company’s stock valued at $185,000 after purchasing an additional 11,943 shares during the period. BSW Wealth Partners acquired a new position in Miragen Therapeutics during the 3rd quarter valued at approximately $203,000. Finally, Aveo Capital Partners LLC acquired a new position in Miragen Therapeutics during the 4th quarter valued at approximately $279,000. Institutional investors and hedge funds own 22.59% of the company’s stock.
Miragen Therapeutics Company Profile
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.